etoposide phosphate (Etopophos)

11/01/1998 - "A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer."
06/01/1995 - "The combination of etoposide phosphate and cisplatin is effective in the treatment of small cell lung cancer, and can be administered with acceptable toxicity. "
06/01/1995 - "The combination of etoposide phosphate and cisplatin is effective in the treatment of small-cell lung cancer, and can be administered with acceptable toxicity. "
07/01/2001 - "We conducted a study to evaluate the efficacy and tolerability of a combination therapy with carboplatin (C) and etoposide phosphate (EP) in elderly patients with Small-Cell Lung Cancer (SCLC). "
07/01/2001 - "Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study."

11/28/2015 - "Etoposide phosphate (EP), a water-soluble anticancer prodrug, is widely used for treatment of many cancers. "
01/01/1997 - "Eleven patients with advanced cancer refractory to standard therapy were treated with etoposide phosphate given over 1-2 hours on three consecutive days. "
12/01/1996 - "A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients."
01/01/1996 - "Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors."
01/01/1995 - "Thirty-nine patients with documented cancers received a total of 75 cycles of etoposide phosphate. "

10/01/1995 - "Etoposide phosphate (EP) is a water-soluble derivative of etoposide (VP-16), a semisynthetic podophyllotoxin which is useful in the treatment of a wide variety of hematological malignancies and solid tumors. "

07/11/2005 - "A pharmacokinetically guided phase I study of topotecan and etoposide phosphate was conducted in recurrent ovarian cancer. "
07/11/2005 - "Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer."

01/01/1990 - "BMY-40481-30 given iv was more active than etoposide given ip in two of five experiments versus iv P388 leukemia, but the two compounds were comparably active in the other three studies. "
01/01/1990 - "Comparison at the MTD of the two compounds showed that BMY-40481-30 administered ip was as active as etoposide against ip P388 leukemia. "
01/01/1990 - "Both etoposide and BMY-40481-30 yielded comparable maximum effects against ic P388 leukemia, ic L1210 leukemia, and sc B16 melanoma, but etoposide was more efficacious versus sc M5076 sarcoma.(ABSTRACT TRUNCATED AT 250 WORDS)"